Related Experiment Video

Updated: Sep 20, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Rationale and risks of novel immunomodulatory therapies in rheumatoid arthritis

J J Cush1

  • 1Arthritis Center, Presbyterian Hospital of Dallas and The University of Texas Southwestern Medical School at Dallas, Dallas, Texas 75231, USA.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed

Insights

Conventional rheumatoid arthritis (RA) treatments show limited efficacy. New biologic therapies are being developed to address RA

Area of Science:

  • Immunology and Rheumatology
  • Biotechnology and Drug Development

Background:

  • Rheumatoid arthritis (RA) is increasingly recognized as a severe condition with significant long-term impacts.
  • Conventional disease-modifying antirheumatic drug (DMARD) therapies demonstrate limited long-term efficacy and tolerability.
  • DMARDs have not proven effective in modifying articular, functional, or radiographic outcomes in RA patients.

Purpose of the Study:

  • To explore the clinical and biologic rationale for novel therapeutic strategies in rheumatoid arthritis.
  • To discuss the potential risks associated with manipulating immune effector mechanisms for RA treatment.

Main Methods:

  • Review of recent studies on DMARD efficacy and tolerability.
  • Analysis of advances in understanding RA immunopathogenesis.
  • Examination of progress in biotechnology for therapeutic development.

Main Results:

  • Conventional DMARDs have shown insufficient long-term effectiveness and tolerability.
  • Significant advancements in understanding RA's immune basis and biotechnology are paving the way for new treatments.
  • A revised approach to conventional DMARD use is emerging alongside new interventions.

Conclusions:

  • There is a critical need for novel therapies for rheumatoid arthritis due to the limitations of current treatments.
  • Advances in immunology and biotechnology support the development of new pharmacologic and biospecific interventions for RA.
  • Careful consideration of the hazards of immune system manipulation is essential when developing new RA therapies.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...